Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164269 | 0.86 | HIF1A (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL11408759 | 0.86 | SLC6A2 (0.69) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL3184095 | 0.86 | HIF1A (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL10327026 | 0.86 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL10326285 | 0.86 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL10326814 | 0.86 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL3164054 | 0.84 | HIF1A (0.69) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL3172811 | 0.83 | HIF1A (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL3174744 | 0.83 | HIF1A (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 | |
| SCHEMBL1794708 | 0.82 | SLC6A3 (0.62) | SLC6A3SLC6A2SLC6A4HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040146542-A1 | Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal | FROELICH OLIVIER | 2004-07-29 | — | — | US | claimed |
| US-20020142023-A1 | Composition for keeping away vermin | NOVARTIS ANIMAL HEALTH US INC. | 2002-10-03 | — | — | US | claimed |
| EP-1087662-B1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 2002-04-10 | — | — | EP | claimed |
| US-20010003646-A1 | Composition for keeping away vermin | FROELICH OLIVIER (FR) | 2001-06-14 | — | — | US | claimed |
| EP-1087662-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | Novartis AG (CH) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065311-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | claimed |
| US-20040146542-A1 | Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal | FROELICH OLIVIER | 2004-07-29 | — | — | US | disclosed |
| US-20020142023-A1 | Composition for keeping away vermin | NOVARTIS ANIMAL HEALTH US INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1087662-B1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 2002-04-10 | — | — | EP | disclosed |
| US-20010003646-A1 | Composition for keeping away vermin | FROELICH OLIVIER (FR) | 2001-06-14 | — | — | US | disclosed |
| EP-1087662-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | Novartis AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065311-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146542-A1 | Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal | PLG, PFN1, CUTA | SLC6A3 1708/4885SLC6A2 661/4885SLC6A4 1605/4885 |
| US-20010003646-A1 | Composition for keeping away vermin | VMP1, SERPINC1, VIL1 | SLC6A3 1305/4885SLC6A2 895/4885SLC6A4 2177/4885 |
| US-20020142023-A1 | Composition for keeping away vermin | VMP1, SERPINC1, VIL1 | SLC6A3 1305/4885SLC6A2 895/4885SLC6A4 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.